Ashton Thomas Private Wealth LLC Has $4.45 Million Holdings in Thermo Fisher Scientific Inc. $TMO

Ashton Thomas Private Wealth LLC boosted its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 4.8% in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 10,958 shares of the medical research company’s stock after acquiring an additional 500 shares during the quarter. Ashton Thomas Private Wealth LLC’s holdings in Thermo Fisher Scientific were worth $4,448,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. CBIZ Investment Advisory Services LLC boosted its position in Thermo Fisher Scientific by 137.5% during the 1st quarter. CBIZ Investment Advisory Services LLC now owns 57 shares of the medical research company’s stock worth $28,000 after acquiring an additional 33 shares during the period. Anderson Financial Strategies LLC acquired a new stake in Thermo Fisher Scientific during the 1st quarter worth about $30,000. Keystone Global Partners LLC acquired a new stake in shares of Thermo Fisher Scientific during the 1st quarter valued at about $31,000. DiNuzzo Private Wealth Inc. lifted its holdings in shares of Thermo Fisher Scientific by 406.7% during the 2nd quarter. DiNuzzo Private Wealth Inc. now owns 76 shares of the medical research company’s stock valued at $31,000 after buying an additional 61 shares during the last quarter. Finally, HighMark Wealth Management LLC lifted its holdings in shares of Thermo Fisher Scientific by 140.6% during the 2nd quarter. HighMark Wealth Management LLC now owns 77 shares of the medical research company’s stock valued at $31,000 after buying an additional 45 shares during the last quarter. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, CAO Joseph R. Holmes sold 385 shares of the business’s stock in a transaction that occurred on Friday, August 29th. The stock was sold at an average price of $492.63, for a total transaction of $189,662.55. Following the sale, the chief accounting officer directly owned 2,319 shares in the company, valued at approximately $1,142,408.97. The trade was a 14.24% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Marc N. Casper sold 400 shares of the company’s stock in a transaction on Friday, September 5th. The shares were sold at an average price of $500.50, for a total value of $200,200.00. Following the completion of the sale, the chief executive officer owned 113,762 shares in the company, valued at $56,937,881. This trade represents a 0.35% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 29,666 shares of company stock worth $13,990,971. 0.33% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on the company. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating on shares of Thermo Fisher Scientific in a report on Thursday. TD Cowen lifted their price target on Thermo Fisher Scientific from $612.00 to $654.00 and gave the company a “buy” rating in a report on Thursday, October 23rd. Royal Bank Of Canada set a $561.00 price target on Thermo Fisher Scientific and gave the company an “outperform” rating in a report on Tuesday, September 2nd. Weiss Ratings reiterated a “hold (c)” rating on shares of Thermo Fisher Scientific in a report on Tuesday, October 14th. Finally, UBS Group boosted their target price on Thermo Fisher Scientific from $500.00 to $590.00 and gave the stock a “neutral” rating in a report on Thursday. Nineteen research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $595.75.

Thermo Fisher Scientific Stock Performance

TMO opened at $564.49 on Tuesday. The stock has a market cap of $213.16 billion, a PE ratio of 32.61, a P/E/G ratio of 3.35 and a beta of 0.77. The company has a current ratio of 1.50, a quick ratio of 1.11 and a debt-to-equity ratio of 0.62. Thermo Fisher Scientific Inc. has a 1 year low of $385.46 and a 1 year high of $610.97. The stock’s 50 day simple moving average is $505.57 and its 200-day simple moving average is $454.34.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings data on Wednesday, October 22nd. The medical research company reported $5.79 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.50 by $0.29. The business had revenue of $11.12 billion for the quarter, compared to analysts’ expectations of $10.90 billion. Thermo Fisher Scientific had a return on equity of 16.97% and a net margin of 15.02%.Thermo Fisher Scientific’s quarterly revenue was up 4.9% on a year-over-year basis. During the same period in the previous year, the business posted $5.28 earnings per share. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. Sell-side analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.